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Abstract
Microglial dysfunction is associated with the pathogenesis and progression of a number of neurodegenerative
disorders including HIV associated dementia (HAD). HIV promotion of an M1 antigen presenting cell (APC) - like
microglial phenotype, through the promotion of CD40 activity, may impair endogenous mechanisms important for
amyloid- beta (Ab) protein clearance. Further, a chronic pro-inflammatory cycle is established in this manner. CD45
is a protein tyrosine phosphatase receptor which negatively regulates CD40L-CD40-induced microglial M1
activation; an effect leading to the promotion of an M2 phenotype better suited to phagocytose and clear Ab.
Moreover, this CD45 mediated activation state appears to dampen harmful cytokine production. As such, this
property of microglial CD45 as a regulatory “off switch” for a CD40-promoted M1, APC-type microglia activation
phenotype may represent a critical therapeutic target for the prevention and treatment of neurodegeneration, as
well as microglial dysfunction, found in patients with HAD.
The Role of Microglia in HIV Associated
Dementia (HAD)
Macrophages and microglia compose some 12% of the
cells in the central nervous system (CNS) [1]. Their
roles include phagocytosis, antigen presentation, as well
as generation and excretion of cytokines, eicosanoids,
complement components, and excitatory amino acids
(EAA) including, glutamate, oxidative radicals, and nitric
o x i d e( N O )[ 2 ] .A tl e a s tt h r e ep h e n o t y p i cs t a t e so f
microglia exist based on developmental and pathophy-
siologic studies: (i) resting, ramified; (ii) activated non-
phagocytic (or APC like) found in areas involved in
central nervous system (CNS) inflammation; and (iii)
reactive, phagocytic microglia observed in areas of
trauma or infection [3-7] (Figure 1).
In regard to activation, macrophages and microglia
are able to polarize into two major subtypes, categorized
as M1 or M2 [8,9]. The “classical” or M1 subtype over-
produces pro-inflammatory cytokines and promotes
cell-mediated immunity [8,9]. It is marked by produc-
tion of high levels of interferon -gamma (IFN-g), tumor
necrosis factor (TNF)-a, interleukin (IL)-1, IL-12, and
low levels of IL-10. The M1 phenotype may be activated
when microglia contact HIV proteins (such as transacti-
vator of transcription [Tat]) [10] bind toll-like receptors
3o r4a sw e l l[ 1 1 ] .“Alternatively activated” or M2
microglia tend to dampen inflammation, clear cellular
debris (including amyloid plaques), and produce very
low levels of TNF-a,I L - 1 ,I L - 1 2a n dh i g ha m o u n t so f
anti-inflammatory IL- 10 and transforming growth fac-
tor (TGF)-b, and SOCS (suppressor of cytokine signal-
ing) [8,9,12,13]. These two phenotypes, respectively,
correspond to the type ii or iii microglial states
described in the preceding paragraph. Further, the fac-
tors which cause polarization to M1 or M2 reinforce
the maintenance of that phenotype in a cycle-like man-
ner (Figure 1). Increased M1 polarization is consistent
with increased TNF-a observed in plasma and brain
specimens in HAD and AD, and may play a role in the
pathophysiology of both diseases [14].
Stimulation of Th1 and Th2 immune response by
microglia is dependent upon the expression of specific
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(MHC) II and CD40 [15]. Microglia expressing MHC II
induce CD4+ T cells to generate IFN-g and TNF-a [16].
In the case of both HAD and AD, this response is con-
sidered harmful to the brain and in both diseases TNF-
a is elevated to neurotoxic levels while only in HAD is
IFN-g is prominently elevated [14].
In HIV associated dementia (HAD; also known as
NeuroAIDS, or HIV encephalitis [HIVE]), microglia
and macrophages are productively infected by HIV-1
and show diffuse inflammatory activation, which ulti-
mately leads to neuronal damage, death, CNS dysfunc-
tion [17,18]. A clinical trial using a small number of
post-mortem HIV-infected individuals showed a direct
correlation between microglial activation/infection and
cognitive decline [19]. Studies have found microglial
HIV infection as central in exacerbating HIV dementia
[20,21]. Importantly, neuronal dysfunction and death
in HIV infection results from cytokine stimulation, but
especially several cytokine-mediated apoptotic mechan-
isms emanating from microglia. Thus microglial cyto-
kine production is central to the pathogenesis of HAD
[22,23].
Indeed, viral infection and/or immune activation of
microglia fuels HAD pathogenesis ending in neuronal-
injury and death [24,25]. Microglia are the main target
for the HIV-1 infection in the brain. The virus infiltrates
the CNS via infected monocytes [26,27]. Once infected
or activated by HIV- proteins such as gp120 or Tat,
microglia begin to excrete endogenous pro-inflammatory
cytokines of the M1 subtype [28].
Histopathologically, activated microglia represent a
highly accurate correlate to neuronal death and damage
in CNS [29]. Severity of dementia in persons with HAD
is strongly correlated with the number of activated
macrophages and microglia within the basal ganglia and
frontal lobes [30,31]. Moreover, activation of microglial
cells by HIV is associated with astrogliosis, myelin pal-
lor, and severe neuronal loss [24,30].
Recently, with the advent of highly active antiretroviral
therapy (HAART) patients with HIV have been living
significantly longer lives. While HAART has been
increasing the lifespan of those infected with HIV, it has
also led to an increased prevalence of HAD [32-38]. As
the pathology of HAD, like Alzheimer’s Disease (AD), is
commonly characterized by an increase in the amount
of amyloid-beta (Ab) peptide in the brain [39], evidence
suggesting microglia modulate the clearance of poten-
tially neurotoxic Ab species from the brain is of special
importance [40,41].
Indeed, microglia play a major role in the neuropatho-
genesis of HAD and AD in quite similar ways, although
the etiology of these diseases differ greatly [14]. Neuro-
pathological similarities between HAD and AD include
cortical neuronal loss and amyloid plaque deposition
[39,42-44]. Indeed, most forms of dementia are accom-
panied by a widespread degeneration in the cerebral
c o r t e x-s u c ha st h ep l a q u e si nA Db r a i n .A Di st h u s
considered a “cortical dementia.” HAD is also consid-
ered to be a cortical dementia however there is also tar-
geted damage to regions lying under the cortex. Some
authors consider HAD to be a subcortical dementia
however this terminology is somewhat inaccurate. HAD
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Figure 1 Modulation of Microglia Phenotypes in HIV associated
dementia (HAD). The roles of microglia include phagocytosis,
antigen presentation, as well as generation and excretion of
cytokines, eicosanoids, complement components, and excitatory
amino acids (EAA) including, glutamate, quinolinic acid (QUIN),
oxidative radicals, and nitric oxide (NO) [2]. At least three
phenotypic states of microglia exist based on developmental and
pathophysiologic studies: (i) resting, ramified; (ii) activated non-
phagocytic (or APC like) found in areas involved in central nervous
system (CNS) inflammation; and (iii) reactive, phagocytic micorglia
observed in areas of trauma or infection [3-7]. In regard to
activation, these cells are able to polarize into two major subtypes:
M1 or M2 [8,9]. M1 subtype over-produces pro-inflammatory
cytokines. It is marked by production of high levels of interferon
-gamma (IFN-g) tumor necrosis factor (TNF)-a, interleukin (IL)-1,
IL-12, and low levels of IL-10 [8,9]. The M1 phenotype may be
activated when microglia contact HIV proteins (such as
transactivator of transcription [Tat]) [10] or bind toll-like receptors 3
or 4 as well [11]. M2 microglia dampen inflammation, become
phagocytic, and produce very low levels of TNF-a, IL-1, IL-12 and
high amounts of anti-inflammatory IL- 10 and transforming growth
factor (TGF)-b, and SOCS (suppressor of cytokine signaling) [12,13].
These two phenotypes, respectively, correspond to the type ii or iii
microglial states described in the preceding paragraph. Further, the
factors which cause polarization to M1 or M2, reinforce the
maintenance of that phenotype in a cycle-like manner [8,9] (Figure
1). Increased M1 polarization is consistent with increased TNF-a
observed in plasma and brain specimens in HAD and AD, and may
play a role in the pathophysiology of both diseases [14]. Stimulation
of Th1 and Th2 immune response by microglia is dependent upon
the expression of specific molecules including major
histocompatibility complex (MHC) II and CD40 [15]. v = viral factors
~ = soluble or cell surface receptor ligation Δ = cytokines and
soluble factors.
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The resulting brain damage is often visualized on MRI
as generalized brain atrophy and also visibly damaged
subcortical areas [45,46].
Amyloid plaques in AD result from the deposition of
amyloid beta (Ab) which is a putative pathogenic mole-
cule in AD. Ab is the cleavage product of the amyloid
precursor protein (APP) and APP mutations are asso-
ciated with inherited forms of AD. The clinical implica-
tion or pathogenic consequences of brain amyloid
deposition are still controversial in the AD field;
although, the finding of Ab deposition in both AD and
HAD strongly suggests parallel pathways of chronic
inflammation-mediated change that eventually yields
cortical dysfunction characterized by identical “biomar-
kers”. For example, decreased cerebrospinal fluid (CSF)
Ab and increased tau (a component of the neurofibril-
lary tangle, a second AD neuropathological hallmark)
have been proposed as sensitive and specific markers of
AD in several studies [47,48]. It has also been found
that changes in CSF Ab and tau are comparable to
those observed in AD and HAD patients [49]. The
pathogenic significance of these biomarkers is not well
established but it has been hypothesized that decreased
CSF Ab indicates increased aggregation of insoluble Ab
and sequestration into amyloid plaques [50].
The mechanisms of neurodegeneration, which are
highly microglia-dependent, in AD and HAD are similar
in many ways as well [14]. Cascades of inflammatory
processes lead to neurodegeneration in both dementias.
The initial step in each disease differs. HAD is second-
ary to infection with HIV-1, while the exact cause of
AD remains to be established. A common feature
among both diseases is the interactions of microglia
which promote a neurotoxic inflammatory environment.
These interactions play significant roles in the initiation
and continuation of the neurodegenerative process in
each disease [14].
In both diseases, whether activation is by HIV itself,
its proteins, or Ab peptides, microglia release cytokines,
reactive oxygen species (ROS), and several neurotoxins
that impair cellular function, neurotransmitter action,
and induce neuronal loss [51,52][14,53]. Some of these
neurotoxins in both forms of dementia include TNF-a,
arachidonic acid, platelet activating factors (PAF), nitric
oxide (NO), and quinolinic acid (QUIN) [17,53-59].
Nitric oxide is synthesized by endothelial cells, neurons,
and macrophages and is thought to be associated with
NMDA-type glutamate-initiated neurotoxicity [54].
TNF-a is released by HIV-1-infected microglia, and
oligodendrocytes are particularly sensitive to its effects
[60]. Steady-state levels of TNF-a mRNA are higher in
the subcortical regions of the CNS of patients with
HAD than in HIV-1-infected patients without CNS
involvement [61]. QUIN is a highly excitotoxic marker
most well known in HIV neurological disease which
may reflect the extent of immune activation in both
blood and the brain and correlates with systemic and
neurological disease status [17,53,55-59].
During immune activation, particularly while levels of
IFN-g are increased, induction of the enzyme indoleamine
2,3-dioxygenase occurs, increasing the synthesis of QUIN
[53,62-64]. HIV-infected microglia also release chemo-
kines [65], which may enhance infiltration and recruitment
of both infected and uninfected microglia [53].
HIV encephalitis is typically marked by the presence
of multinucleated giant cells and microglial nodules by
immunohistochemistry or in situ hybridization. The pre-
sence of microglia in the CNS is strongly associated
with severe neurobehavioral complications [66-69].
Microglia, as a major target of HIV-1 infection in the
CNS, are typically a viral reservoir [70-72] and are also
key in HIV-1 neuroinvasiveness-penetration into the
CNS by the virus [72,73]. Most importantly, a discre-
pancy between the localization of HIV-infected cells and
the severity of neurocognitive symptoms has been
described [74-76]. Thus, other mechanisms secondary to
virus infection, such as passage of monocytes and lym-
phocytes into the brain, activation of astrocytes/micro-
glia, and production and release of inflammatory
cytokines, all participate in the pathogenesis of HAD.
This is a key concept which makes the neuropathogen-
esis of HAD, in many ways, similar to that of AD.
b-amyloid is a potent and direct neurotoxic agent
[77-79], much like the HIV-1 proteins gp120 and Tat, and
it induces a cascade of cellular mechanisms including acti-
vation of microglia [80], which leads to neuronal damage
[81]. Indeed, reactive microglia are closely associated with
neuritic and b-amyloid plaques, just as they are with HIV-
1 Tat protein [82-89]. Using electron microscopic techni-
ques, interactions between microglia and astrocytes have
been observed [90], which may be associated with the pro-
duction of cytokines that are also over-produced in the
HAD brain such as IL-1b,t u m o rT N F - a, complement
proteins, and ROS [81,91-94]. Research by our group and
others of the microglia signal transduction pathways med-
iating the neurotoxic response of Ab demonstrated that
mitogen-activated protein-kinase (MAPK) superfamily
members ERK1/2 and p38 MAPK act as mediators
[95-97]. Furthermore, several lines of evidence indicate the
NF-B in microglia is stimulated by b-amyloid [98,99].
Activation of NF-B can stimulate transcription of genes
expressing TNF-a, IL-1, IL-6, monocytes chemo-attractant
protein-1(MCP-1), and nitric oxide synthase (NOS). This
too is re-capitulated in HAD as several lines of evidence
indicate HIV gp120 and Tat activate the same pathway,
leading to the production of the same neurotoxins
[88,89,100-103].
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infected brain, microglial phagocytosis of Ab1-42 peptide
appears inhibited [35]. The deposition of Ab plaques in
the HIV-1 infected brain is likely caused by several fac-
tors including the effects of cytokines and HIV-1 pro-
teins on microglial phenotype, activation and activity.
IFN-g is hypothesized to enhance the effects of HIV-1
Tat by promoting the switch from a microglial phagocy-
tic phenotype to one that is an antigen presenting cell
(APC) phenotype [37].
Modulation of Microglial activation in HAD: CD40,
CD40L, sCD40L and CD45
CD40L is a 33-kDa type II membrane glycoprotein that
is predominantly expressed by activated T cells, B cells,
myeloid cells, and platelets. It has been well established
that CD40L upregulates the immune response by lead-
ing to increased CD4+ T cell activation; an effect which
promotes the replication of HIV in infected lymphocytes
and immune cells [104] and also that robust CD40 liga-
tion promotes an inflammatory and neurotoxic environ-
ment in the brain [105,106].
Elevated levels of sCD40L are found in an array of
neurodegenerative diseases including HAD, AD, and
multiple sclerosis (MS) [106]. This soluble protein is
thought to initiate or potentiate an inflammatory cycle
[106-109] in these conditions. Indeed, inflammation
upregulates expression of CD40 receptor on the sur-
face of endothelial cells and the shedding of the ligand
[110]. Inhibition of CD40-CD40L interactions was
shown to retard the development of experimental
autoimmune encephalomyelitis (EAE), in an animal
model of MS [111]. In vitro studies demonstrated IFN-
g, which is overexpressed in the HIV infected brain
[112] up-regulates the expression of CD40 by microglia
[113,114]. In AD it has been shown that blood vessels
and reactive microglia stain positively for CD40 in
post-mortem b r a i nt i s s u e s .A l s oi nA Db r a i n ,a g g r e -
gates of reactive microglia express CD40 in senile pla-
ques. Up-regulation of CD40 expression by microglia
is also seen in a variety of brain lesions without Ab
deposits. They include multiple sclerosis plaques [111]
as well as lesions of adrenoleukodystrophy, DRPLA,
and ischemic strokes [115]. Ab was also shown to
induce CD40 expression by cultured microglia
[116,117] and cultured vascular endothelial cells
[116,118][118-120]. HIV-1 induces the latter phenom-
enon as well [121] It may be the mechanism by which
CD40 expression is up-regulated in and around senile
plaques in both diseases. However, the results of this
study suggest that CD40 expression is induced upon
multiple stimuli and that CD40-CD40L interactions are
involved rather ubiquitously in activation of microglia
and vascular cells.
In regard to HIV-1 neuropathogenesis, a link between
CD40 and microglia has been established. Upregulation
of CD40 expression has been detected on microglia of
HIV-1-infected brain tissues [28]. CD40L was also
shown to potentiate the ability of HIV-1 Tat to activate
monocytes and microglia leading to the overproduction
of inflammatory proteins such as cytokines and chemo-
kines [122].
Furthermore HAART is unable to modulate blood
brain barrier (BBB) leakage and inflammation in HAD
patients [29,123] in part because it does not reduce the
elevated levels of CD40 ligand (CD40L) found in the
plasma and CSF of HIV-1-infected patients [122,124]. In
further confirmation, other systems [125-127] have
shown high levels of sCD40L can modulate CNS inflam-
mation at the level of the BBB.
High levels of soluble CD40L in CSF and plasma of
HIV-infected patients with cognitive impairment has
been demonstrated as well. Exposure of primary human
brain microvascular endothelial cells (BMVECs) to
CD40L increased the expression of adhesion molecules
intracellular adhesion molecule-1 and vascular cell adhe-
sion molecule-1, which yielded a fourfold increase in
monocyte adhesion to BMVECs and stimulated migra-
tion across an in vitro BBB model [128].
Also central to microglial regulation in HAD, higher
levels of sCD40L have been found in the blood and CSF
of HIV-infected patients with cognitive impairments
compared with HIV-infected subjects without cognitive
impairment. Further assays from the same study showed
CD40L synergized with HIV-1 Tat to increase TNF-a
release from primary human monocytes and microglia,
in an NF-B-dependent manner [122].
Several basic science studies have shown that, during
HAD as well as AD, CD40 upregulates the NF-Bp a t h -
way, causes hyperactivity in microglia and macrophages,
which then produces the release of several neurotoxic
compounds such as TNF-a further exacerbating neuro-
degeneration (for further review see [97,105,106]). In
addition, CD40 activation increases inflammatory
responses and decreases the clearance of Ab. Disrupting
CD40 activation by opposing CD40L activity has shown
important in improving spatial memory in animal mod-
els of AD [117,118,129,130]. Data from our group and
others demonstrate the negative regulation of CD40
activation on microglial cells by CD45 [82].
Indeed in contrast to CD40, one cell surface receptor
that has been implicated in inhibiting microglial activa-
tion is the protein-tyrosine phosphatase (PTP) protein,
CD45. It is especially effective at inhibiting microglial
activation because its action takes place far upstream
from proinflammatory intracellular mediators. We have
shown that cross linking CD45 markedly reduces micro-
glial activation resulting from Ab peptide [131].
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MAPK pathway; thereby abrogating microglial activation
[131]. Mice brains deficient in CD45 have been shown
to have increased levels of potentially neurotoxic cyto-
k i n e ss u c ha sT N F - a [131]. Taken together, these data
seem to suggest that CD45 opposes microglial activation
induced by the presence of Ab peptide.
In addition to its inhibitory effect on Ab induced
microglial activation, CD45 has been shown to inhibit
microglial activation induced by several other proinflam-
matory stimuli [131]. When microglia are incubated with
CD45 cross-linking antibodies and LPS, activation was
significantly attenuated as evidenced by decreased levels
of the neurotoxins TNF-a and NO [131]. This suggests
that cross linked CD45 acts to inhibit microglial activa-
tion induced by LPS [131]. Other studies also implicate
the role of CD45 in negatively regulating cytokine recep-
tor signaling [132,133]. CD45 sufficient macrophages
were able to induce greater Ab clearance, reduced pro-
inflammatory (TNF-a) and increased anti-inflammatory
(IL-10) cytokines, as well as, potentiate growth factors
(TGFb) in mouse brain. Further, CD45 has also been
shown to downregulate NF-kappaB, an important media-
tor of proinflammatory cytokines and is expressed at a
higher rate in HIV infected cells vs. normal cells [134].
Also, matrix metalloproteinase-9 (MMP-9), a protein
shown to decrease Ab plaque formation, was significantly
elevated following CD45 administration [135].
In using CD45 to characterize various isoforms of a
microglial surface receptor target, our prior studies
found that CD45 is able to antagonize CD40L/CD40
mediated-microglia activation [136]. CD45 may perform
this function by modulating the production of IL-2,
IL-10, and other cytokines and inflammatory factors
[97]. Further, co-treatment of microglia with CD40L, in
the presence of CD45 activating antibody, results in sig-
nificant inhibition of microglial TNF-a production
through inhibition of p44/42 MAPK activity [82].
In HIV infected patients CD45 expression is decreased.
Although this study did not analyze HAD, a lower
expression of these proteins on immune cells as well as a
higher presence of CD8+ lymphocyte count in HIV+
patients, but not controls, suggests multifactorial
immune dysregulation in HIV infected patient; including
CD45 dysregulation [137]. Impaired functioning of CD45
is also observed in HIV infected cell cultures. Indeed dys-
regulated CD45 function likely plays a key role in the
inhibition of CD3/CD4 signaling thus contributing to
HIV-1 pathogenesis [138]. CD45 antibodies can suppress
HIV-infected microglial proliferation, as well as, potently
inhibit HIV replication, both in vitro and in vivo.M i c r o -
glia that contain CD45 agonist antibody are able to inhi-
bit HIV-1 replication in human cells [139]. Accordingly,
HIV infected T-cells display lower levels of CD45
protein; perhaps pointing to a subpopulation susceptible
to virus infection or an effect of the virus or viral pro-
ducts on these cells. Indeed, CD45 antibodies have the
potential to suppresses neuroinflammation in HAD, AD,
and other inflammatory CNS diseases [27,82,131].
In summary, numerous investigations suggest that CD45
plays a key role in regulation of CD40L/CD40-induced
microglial activation. This property of microglial CD45 as
a regulatory “off switch” for a CD40 promoted, APC-type,
M2 type microglia activation phenotype is very likely criti-
cal for the prevention and treatment of neurodegeneration
found in patients with HAD (Figure 1).
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